JPS55136233A - Hb peptide vaccine - Google Patents

Hb peptide vaccine

Info

Publication number
JPS55136233A
JPS55136233A JP4405879A JP4405879A JPS55136233A JP S55136233 A JPS55136233 A JP S55136233A JP 4405879 A JP4405879 A JP 4405879A JP 4405879 A JP4405879 A JP 4405879A JP S55136233 A JPS55136233 A JP S55136233A
Authority
JP
Japan
Prior art keywords
hepatitis
hbsag
virus
surface antigen
antigenicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP4405879A
Other languages
Japanese (ja)
Other versions
JPS6212238B2 (en
Inventor
Hiroyuki Shiraishi
Riyouichi Shirochi
Nakao Ishida
Satoru Funakoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Priority to JP4405879A priority Critical patent/JPS55136233A/en
Publication of JPS55136233A publication Critical patent/JPS55136233A/en
Publication of JPS6212238B2 publication Critical patent/JPS6212238B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NEW MATERIAL:HBsAg. A peptide having the following physico-chemical properties, obtained by heat-treating the surface antigen of hepatitis B virus in the presence of a surfactant and a reducing agent: Molecular weight 18,000W23,000. Solubility: about 5% or less in water near neutral, assuming a proteinous opaque color at a higher concentration. Ultraviolet adsorption: molecular extinction coefficient at 280nm of 38. Temperature stability: without loss of the antigenicity of an aqueous solution if heated at 60±0.5°C for 1hr. Constitutent amino acids: 17 amino acids, e.g., aspartic acid and threonine.
USE: Vaccines for hepatitis B. Low-molecular subunits capable of retaining the antigenicity of the surface antigen (HBsAg) of the hepatitis B virus (HBV).
PROCESS: The vaccine is obtained from blood plasma or serum comprising the surface antigen (HBsAg) of hepatitis B virus.
COPYRIGHT: (C)1980,JPO&Japio
JP4405879A 1979-04-11 1979-04-11 Hb peptide vaccine Granted JPS55136233A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4405879A JPS55136233A (en) 1979-04-11 1979-04-11 Hb peptide vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4405879A JPS55136233A (en) 1979-04-11 1979-04-11 Hb peptide vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP628688A Division JPS63239234A (en) 1988-01-14 1988-01-14 Vaccine preparation

Publications (2)

Publication Number Publication Date
JPS55136233A true JPS55136233A (en) 1980-10-23
JPS6212238B2 JPS6212238B2 (en) 1987-03-17

Family

ID=12681007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4405879A Granted JPS55136233A (en) 1979-04-11 1979-04-11 Hb peptide vaccine

Country Status (1)

Country Link
JP (1) JPS55136233A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60258127A (en) * 1984-06-04 1985-12-20 Green Cross Corp:The Preparation of hepatitis b vaccine
WO1995015497A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Immunoassay for cervical cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOUNAL OF VIROLOGY=1972 *
PROC NATL ACAD SCI USA=1977 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60258127A (en) * 1984-06-04 1985-12-20 Green Cross Corp:The Preparation of hepatitis b vaccine
WO1995015497A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Immunoassay for cervical cancer

Also Published As

Publication number Publication date
JPS6212238B2 (en) 1987-03-17

Similar Documents

Publication Publication Date Title
CA1207229A (en) Sterilized plasma and plasma derivatives and process therefor
US4591505A (en) Process for inactivating hepatitis B virus
ATE125821T1 (en) VACCINE AGAINST HEPATITIS B.
PT101052A (en) Hybrid proteins useful in the preparation of vaccines
NO167359C (en) PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST INFECTION OF HEPATITIS B VIRUS.
DE3381472D1 (en) RECOMBINANT DNA CONTAINING HEPATITIS B VIRUS GENE, MAMMALINE CELLS TRANSFORMED WITH THE CLONED VIRAL DNA AND PRODUCTION OF HEPATITIS B VIRUS PROTEINS.
Fricke et al. Viral safety of clotting factor concentrates
DK57284A (en) PROCEDURE FOR INACTIVATING A LIPID VIRUS
JPS55136233A (en) Hb peptide vaccine
JPS55136234A (en) Hb glycopeptide vaccine
RU2007106900A (en) IMMUNOGENIC COMPLEXES, METHOD FOR THEIR PREPARATION AND THEIR APPLICATION IN PHARMACEUTICAL COMPOSITIONS
Stephan et al. Modulation of hepatitis B infection by intravenous application of an immunoglobulin preparation that contains antibodies to hepatitis B e and core antigens but not to hepatitis B surface antigen
DE69130724T2 (en) Process for obtaining recombinant hepatitis B virus (HEP B) surface antigen
EP0967223A3 (en) Hepatitis C virus peptide antigens and a method of testing for the hepatitis C virus (HCV)
US4946676A (en) Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
Pillot et al. Immunochemical structure of the hepatitis B surface antigen vaccine—I. Treatment of immobilized HBsAg by dissociation agents with or without enzymatic digestion and identification of polypeptides by protein blotting
Mitamura Epidemiology of HDV infection in Japan
JPS51118825A (en) A process for preparing heat stable iga and igm
ATE409705T1 (en) PRE-S PROTEIN OF HEPATITIS B VIRUS (HBV) AS AN ADJUVANT AND COMPONENT OF AN HBV VACCINE
DK257887A (en) PROCEDURE FOR PREPARING HBCAG IN YEARS AND PLASMID TO USE IN EXERCISE OF THE PROCEDURE
JPS57175127A (en) Substance and vaccine related to hepatitis nanb-1 and nanb-2 viral antigen
JPS55164630A (en) Freeze-dried preparation of anti-hbs globulin
KR950704494A (en) Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV))
EP0485347A3 (en) Recombinant hepatitis delta antigen, process for the purification and use thereof
Lord et al. Laser Raman spectroscopy of biomolecules: Structural studies of ragweed allergen Ra5